Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
QuantumSi Inc (QSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: QSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $2.83
Year Target Price $2.83
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.49% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 357.82M USD | Price to earnings Ratio - | 1Y Target Price 2.83 |
Price to earnings Ratio - | 1Y Target Price 2.83 | ||
Volume (30-day avg) - | Beta 2.91 | 52 Weeks Range 0.61 - 5.77 | Updated Date 06/29/2025 |
52 Weeks Range 0.61 - 5.77 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2982.42% |
Management Effectiveness
Return on Assets (TTM) -25.22% | Return on Equity (TTM) -40.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 137274326 | Price to Sales(TTM) 103.93 |
Enterprise Value 137274326 | Price to Sales(TTM) 103.93 | ||
Enterprise Value to Revenue 39.87 | Enterprise Value to EBITDA 0.63 | Shares Outstanding 163560992 | Shares Floating 146748948 |
Shares Outstanding 163560992 | Shares Floating 146748948 | ||
Percent Insiders 13.94 | Percent Institutions 31.75 |
Analyst Ratings
Rating 4 | Target Price 2.83 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
QuantumSi Inc
Company Overview
History and Background
QuantumSi Inc. was founded in 2013. It is focused on developing next-generation protein sequencing technology. It went public via a SPAC merger in 2021. Milestones include developing and launching its Platinum protein sequencing platform.
Core Business Areas
- Protein Sequencing Technology: Develops and commercializes a protein sequencing platform (Platinum) based on next-generation semiconductor chip technology.
Leadership and Structure
Dr. Jonathan Rothberg is the founder and Chairman of the Board. More specific details on the leadership team and organizational structure are available in company SEC filings and the company website.
Top Products and Market Share
Key Offerings
- Platinum: QuantumSi's Platinum is a protein sequencing platform that leverages semiconductor chip technology. Competitors include traditional protein analysis methods and other emerging protein sequencing technologies. Specific market share data is not readily available, as this is a nascent market. The number of users and revenue are not disclosable.
Market Dynamics
Industry Overview
The protein sequencing market is an emerging field with significant growth potential, driven by increasing demand for proteomics research and personalized medicine.
Positioning
QuantumSi aims to be a leader in protein sequencing by offering a high-throughput, cost-effective platform. Its competitive advantage lies in its use of semiconductor technology.
Total Addressable Market (TAM)
The TAM for protein sequencing is estimated to be in the billions of dollars. QuantumSi is positioned to capture a portion of this market by offering a novel technology platform.
Upturn SWOT Analysis
Strengths
- Novel Semiconductor-Based Protein Sequencing Technology
- High-Throughput Capabilities
- Potential for Cost-Effectiveness
- Experienced Leadership Team
Weaknesses
- Relatively New Company
- Limited Commercial Track Record
- Dependence on Single Product (Platinum)
- Unprofitable
Opportunities
- Growing Protein Sequencing Market
- Partnerships with Pharmaceutical and Research Institutions
- Expansion into New Applications (e.g., diagnostics)
- Further Technological Advancements
Threats
- Competition from Established Protein Analysis Methods
- Emergence of Other Novel Protein Sequencing Technologies
- Regulatory Hurdles
- Economic Downturn
Competitors and Market Share
Key Competitors
- ILMN
- PACB
- AVNW
- QDEL
Competitive Landscape
QuantumSi's advantage lies in its semiconductor-based technology, but it faces competition from established players with broader product portfolios and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the early stage of commercialization.
Future Projections: Future growth projections depend on the adoption of the Platinum platform and are subject to analyst estimates, which can be found on financial analysis websites.
Recent Initiatives: Recent initiatives include product launches, partnerships, and expansion of manufacturing capacity.
Summary
QuantumSi is an early-stage company developing innovative protein sequencing technology. Its semiconductor-based platform has the potential to disrupt the market, but it faces challenges related to commercialization and competition. The company's financial health relies on successful adoption of its Platinum platform and partnerships. Investors should monitor its progress in penetrating the market and managing its cash flow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- QuantumSi Inc. SEC Filings
- QuantumSi Inc. Investor Relations
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company-specific factors can change rapidly, and investors should conduct their own due diligence before making any investment decisions. Market share data is approximate and may vary based on different sources and methodologies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About QuantumSi Inc
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-10 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.